FDA reviewing safety of infant RSV injections

The mainstream summary does not mention the significant disparities in RSV infection rates among different racial and ethnic groups. In 2022, the peak infection rate for Black children under 5 years was 2,135 cases per 1,000,000 person-days, which is 195% higher than that for White children, while Hispanic children faced an even steeper rate of 2,734 cases per 1,000,000 person-days, 278% higher than White children. This context highlights the urgent need for effective interventions like the injectable RSV drugs currently under review, particularly in communities disproportionately affected by the virus. Furthermore, while the FDA's review is critical, it is important to note that treatment-related adverse events were reported in 2.1% of infants in the nirsevimab group, indicating potential safety concerns that warrant close scrutiny during the assessment process. These statistics underscore the complexities surrounding the safety and efficacy of RSV treatments, particularly in vulnerable populations, which the mainstream summary does not fully address.^[1][2]